Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer

Despite effective strategies, resistance (R) in HER2+ breast cancer (BC) remains a challenge. While the Mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2+ models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2+ BC cells...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Res
Hlavní autoři: Sethunath, Vidyalakshmi, Hu, Huizhong, Angelis, Carmine De, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M., Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L., Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C., Reis-Filho, Jorge S., Weigelt, Britta, Heiser, Laura M., Hilsenbeck, Susan G., Huang, Shixia, Rimawi, Mothaffar F., Gray, Joe W., Osborne, C. Kent, Schiff, Rachel
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825570/
https://ncbi.nlm.nih.gov/pubmed/31420371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-0756
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky